The aim of this trial was to investigate the safety of intravenous neridronic acid in
patients with complex regional pain syndrome (CRPS).
The trial was divided into 3 periods: a 60-day enrollment period, a treatment period
consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks
(with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52).